Supply Chain Intelligence

Opus Genetics, Inc. Supply Chain

IRD supply chain intelligence for Opus Genetics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

IRD ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

9Suppliers
7Customers
3Debt Items
20Related Chains

Opus Genetics, Inc. Suppliers

TickerNameConfidenceEvidence
OPCM-SA-LLC OPCM-SA-LLC 92% As previously disclosed, on April 2, 2026, Opus Genetics, Inc., a Delaware corporation (the “Company”), and certain of its subsidiaries as guarantors, entered into a senior secured note purchase agre…
MASSACHUSETTS-EYE-AND-EAR-INFIRMARY MASSACHUSETTS-EYE-AND-EAR-INFIRMARY 90% In return for these rights, the Company is obligated to make certain development milestone payments and royalty payments on future sales of such products.
PENN-AND-UF PENN-AND-UF 90% In return for these rights, the Company is obligated to make certain development milestone payments and royalty payments on future sales of such products.
MYGN Myriad Genetics, Inc. 72% Reciprocal relationship from MYGN graph: Reciprocal relationship from IRD graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from IRD graph: patent application. In addition, such…
MYGN Myriad Genetics, Inc. 72% patent application. In addition, such interference, re-examination, opposition, post-grant review, inter partes review, supplemental examination, or revocation proceedings may be costly or time-consu…
OCUL Ocular Therapeutix, Inc. 72% line products, our business will be materially harmed. • Others may discover, develop, or commercialize products similar to those in our pipeline before or more successfully than we do or develop gen…
OCUL Ocular Therapeutix, Inc. 72% Reciprocal relationship from OCUL graph: Reciprocal relationship from IRD graph: line products, our business will be materially harmed. • Others may discover, develop, or commercialize products simil…
ORANY ORANY 72% place. A request for proposal process, to include small scale process development, technical transfer, and analytical method development, to identify a manufacturing partner is being conducted. The o…
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from IRD graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from IRD graph: place. A request for proposal proce…

Opus Genetics, Inc. Customers

TickerNameConfidenceEvidence
VIATRIS VIATRIS 92% The Company will be eligible to receive potential additional payments of up to $130 million upon achieving certain specified regulatory or net sales milestones, with the first milestone payment of $1…
MYGN Myriad Genetics, Inc. 72% patent application. In addition, such interference, re-examination, opposition, post-grant review, inter partes review, supplemental examination, or revocation proceedings may be costly or time-consu…
MYGN Myriad Genetics, Inc. 72% Reciprocal relationship from MYGN graph: Reciprocal relationship from IRD graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from IRD graph: Reciprocal relationship from MYGN gra…
OCUL Ocular Therapeutix, Inc. 72% Reciprocal relationship from OCUL graph: Reciprocal relationship from IRD graph: line products, our business will be materially harmed. • Others may discover, develop, or commercialize products simil…
OCUL Ocular Therapeutix, Inc. 72% line products, our business will be materially harmed. • Others may discover, develop, or commercialize products similar to those in our pipeline before or more successfully than we do or develop gen…
ORANY ORANY 72% utics (LNZ100 - 1.75% Aceclidine) and AbbVie (VUITY® (pilocarpine hydrochloride ophthalmic solution) - 1.25%). We are not aware of direct competition for the treatment of DLD following keratorefracti…
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from IRD graph: utics (LNZ100 - 1.75% Aceclidine) and AbbVie (VUITY® (pilocarpine hydrochloride ophthalmic solution) - 1.25%). We are…

Opus Genetics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
IRD-DEBT Debt stack $1.1M 90% Market cache reports total debt of $1.1M.
IRD-DEBT-10355 Warrants outstanding: 9.6 90% xbrl warrant detail from xbrl 2025-12-31.
IRD-DEBT-10356 Xbrl Convertible 90% xbrl convertible detail from xbrl 2025-12-31.

Opus Genetics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Opus Genetics, Inc..

Opus Genetics, Inc. Ownership

HolderNameConfidenceEvidence
IRD-OWNER-CALIGAN-PARTNERS-LP Caligan Partners LP 90% 13F overlay lists Caligan Partners LP as top holder; 79 tracked holders.

Opus Genetics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
ATYR aTyr Pharma, Inc. 100.00 2
TEM Tempus AI, Inc. 100.00 2
TECX Tectonic Therapeutic, Inc. 100.00 2
ELVN Enliven Therapeutics, Inc. 100.00 2
HOWL Werewolf Therapeutics, Inc. 100.00 2
GH Guardant Health, Inc. 100.00 2
ORANY ORANGE 100.00 1 ['customer', 'supplier']
SDGR Schrödinger, Inc. 100.00 2
BNBX BNB Plus Corp. 100.00 2
CABA Cabaletta Bio, Inc. 100.00 2
BIAF bioAffinity Technologies, Inc. 100.00 2
IMNM Immunome, Inc. 100.00 2
TPST Tempest Therapeutics, Inc. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
BNTC Benitec Biopharma Inc. 100.00 2
CALC CalciMedica, Inc. 100.00 2
ALLO Allogene Therapeutics, Inc. 100.00 2
DSGN Design Therapeutics, Inc. 100.00 2
PSNL Personalis, Inc. 100.00 2
KDK Kodiak AI, Inc. 100.00 2
View IRD supply chain intel →

Explore the full interactive supply chain map for Opus Genetics, Inc..

Open IRD supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map